Industry updates from the field of stem cell research and regenerative medicine in January 2023-Reference-Cited by-同舟云学术

Industry updates from the field of stem cell research and regenerative medicine in January 2023

Published:2023-05 Issue:5 Volume:18 Page:363-372
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Ilic Dusko¹^ORCID,Liovic Mirjana²^ORCID

Affiliation:

1. Stem Cell Laboratories, Guy's Assisted Conception Unit, Department of Women & Children's Health, Faculty of Life Sciences & Medicine, King's College London, London, SE1 9RT, UK

2. Medical Center for Molecular Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia

Abstract

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in January 2023.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2023-0045

Reference42 articles.

1. Triumvira. Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors (2023). https://triumvira.com/triumvira-immunologics-establishes-collaboration-with-merck-to-evaluate-tac01-her2-cell-therapy-in-combination-with-keytruda-pembrolizumab-in-patients-with-her2-positive-solid-tumors/

2. NCT04727151. TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2) (2023). https://clinicaltrials.gov/ct2/show/NCT04727151

3. Fate Therapeutics. Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives (2023). https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-termination-collaboration-agreement

4. BusinessWire. Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors (2023). www.businesswire.com/news/home/20230123005787/en/Kirby-M…-Class-Action-on-Behalf-of-Fate-Therapeutics-Inc.FATE-Investors

5. PR Newswire. CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China (2023). www.prnewswire.com/news-releases/carsgen-therapeutics-and-huadong-medicine-announce-collaboration-agreement-for-zevorcabtagene-autoleucel-in-mainland-china-301722244.html